Decision Diagnostics Climbs on New Test Strip Design

Decision Diagnostics Climbs on New Test Strip Design

By: Dylan Sikes – News

Tuesday, April 23, 2019

More developments on the health front emerged Tuesday, of special interest to those with diabetes or loved ones attempting to look after them. 

Los Angeles-based Decision Diagnostics Corp. (OTC:DECN), a diabetes-focused bio-technology R&D firm, announced Tuesday that its Korean R&D group, with DECN CEO Keith Berman and his Stoney Fork new products experts, have designed a method and determined meter specifics for the adding of the company's TBG technology to the upcoming GenChoice test strip now in Food and Drug Administration (FDA) 510K review. 

Development of this newer version of the already new GenChoice test strip will be six months from the engineering feasibility to the filing of the 510K with the FDA.

DECN stock climbed 29-100ths of a cent, or 6.4%, to 4.79 cents, early Tuesday afternoon on volume of 183,000


Copyright © 2019 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

In A Sea Of Losses, This Micro Cap Looks Ready For Take Off
Max Trumpets Assays from Colombian Mine
CTD Hikes on Niemann-Pick Treatment Trials
Millrock Stakes More Claims in Alaska Mine

Back to Top